Special Issue "Advances in Antibacterial Drug Discovery and Therapy"
Deadline for manuscript submissions: closed (15 February 2019)
On behalf of the Journal of Clinical Medicine (JCM) editorial team, we are delighted to present a new Special Issue on the topic of “Advances in Antibacterial Drug Discovery and Therapy”, Guest Edited by Dr. Dianqing Sun, from the University of Hawaii at Hilo, USA.
Bacterial infections caused by Mycobacterium tuberculosis and other clinically significant pathogenic bacteria pose growing and serious threats to global public health. This problem is further compounded by mounting antibacterial drug resistance, limited antimicrobial therapy options, and the overall lack of new antibacterial development by the pharmaceutical industry. According to the Centers for Disease Control and Prevention (CDC), in the United States alone, there are more than two million illnesses and 23,000 deaths every year resulting from antibiotic-resistant bacterial infections, with added healthcare costs of about 20 billion dollars. In addition, a 2013 CDC report assigned Clostridium difficile (C. difficile), carbapenem-resistant Enterobacteriaceae, and drug-resistant Neisseria gonorrhoeae into the antibiotic resistance “urgent threat” category. C. difficile remains the most common cause of hospital-acquired diarrhea and can lead to a life-threatening infection or inflammation, particularly among the elderly. In the US, C. difficile is responsible for about 500,000 cases of infections and approximately 15,000 deaths each year, with added healthcare costs of one billion dollars. Notably, for drug resistant and more difficult-to-treat organisms including some gram-negative pathogens, older, more toxic, and costly last-resort antibiotics are increasingly being used to combat these serious infections. As a result, superbugs resistant to the last-resort antibiotics have also been on the rise. Therefore, there is a significant need to develop the next generation of safe antibiotics with improved efficacy and antibacterial resistance profiles.
This Special Issue highlights some recent and historical advances in antibacterial drug discovery and development. Topics may include, but are not limited to, natural product antibacterial drug discovery, small molecule antimicrobial agents, target identification and validation, hit to lead and lead optimization, structure-based design, combination antibiotic therapy, and clinical practice guidelines.
Dr. Dianqing Sun
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- antibacterial drug discovery and development
- antimicrobial resistance
- medicinal chemistry
- structure–activity relationship
- chemical synthesis
- rational design
- computational modeling
- natural product drug discovery
- bacterial therapy
- clinical practice